Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting

Next Previous
Trial Profile

Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Obesity
  • Focus Therapeutic Use
  • Acronyms SCALE IBT
  • Sponsors Novo Nordisk

    • Most Recent Events

    • 18 Mar 2019 Results of a pre-specified secondary analysis assessing athe effect of liraglutide 3.0 mg on weight loss, presented at the 101st Annual Meeting of the Endocrine Society
    • 18 Mar 2019 Results of a pre-specified exploratory sub-analysis determining the individual contributions of adherence to study medication, and to the adjunct diet and physical activity interventions on weight change, presented at the 101st Annual Meeting of the Endocrine Society.
    • 18 Mar 2019 Primary endpoint (Proportion of subjects losing at least 5% of baseline body weight) has been met, according to the results presented at the 101st Annual Meeting of the Endocrine Society.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top